Paul Modlinger, MD
Nephrology · Fairfax, VANPI 1053405688
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 45.8% of the total. Reporting peaked in 2019 at $5,615 and has fallen 82.9% since, to $960 in 2025. Among nephrology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $108.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$8K
- ANI Pharmaceuticals, Inc.$6K
- Mallinckrodt Hospital Products Inc.$880
- AstraZeneca$313
- Mallinckrodt Enterprises LLC$237
- Amgen$182
- plus $2K from 18 others
What the payments were for
- Consulting fees$1,2757%
- Speaking & faculty fees$10,05156%
- Travel & lodging$1,6239%
- Food & beverage$4,40525%
- Education$5623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $8,207 |
| ANI Pharmaceuticals, Inc. | 34 | $6,363 |
| Mallinckrodt Hospital Products Inc. | 22 | $880 |
| AstraZeneca(2 entities) | 13 | $313 |
| Mallinckrodt Enterprises LLC | 7 | $237 |
| Amgen | 7 | $182 |
| Recor Medical Inc | 3 | $179 |
| Vifor Pharma, Inc. | 3 | $179 |
| Bayer | 4 | $176 |
| OPKO Pharmaceuticals, LLC | 8 | $146 |
| Fresenius USA Marketing, Inc. | 8 | $144 |
| Teva Pharmaceuticals USA, Inc. | 1 | $139 |
| Akebia Therapeutics Inc | 5 | $107 |
| Ardelyx, Inc. | 1 | $103 |
| Sanofi | 1 | $103 |
| Novartis | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Aurinia Pharma U.S., Inc. | 1 | $97 |
| Novo Nordisk | 2 | $44 |
| Travere Therapeutics, Inc. | 6 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Medtronic | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$7,489
- PURIFIED CORTROPHIN GEL$5,819
- ACTHAR$374
- AJOVY$139
- Paradise Ultrasound Renal Denervation System$134
- FARXIGA$115
- Kerendia$114
- XPHOZAH 30 MG$103
- THYMOGLOBULIN$103
How this compares
$17,916 in reported general payments places this provider in the 90th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 70 | $80,277 |
| JardianceEmpagliflozin | 56 | $69,124 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $48,320 |
| ProcritEpoetin Alfa | 11 | $24,496 |
| Cinacalcet Hcl | 20 | $14,634 |
| Sevelamer Carbonate | 19 | $8,243 |
| Eplerenone | 41 | $4,936 |
| Potassium Citrate ErPotassium Citrate | 28 | $4,123 |
| Torsemide | 119 | $2,498 |
| Midodrine Hcl | 14 | $1,997 |
| Calcitriol | 73 | $1,176 |
| Nifedipine ErNifedipine | 29 | $848 |
| Tacrolimus | 11 | $796 |
| Losartan Potassium | 79 | $776 |
| Spironolactone | 71 | $717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $313 | $80,27770 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $6,363 | $46413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 298 nephrology providers in Virginia.
Other nephrology in Fairfax
- Reza ZonoziFairfax$262K
- Renuka SothinathanFairfax$68K
- Ali AssefiFairfax$64K
- Kinjal PatelFairfax$31K
- Magnus IkhinmwinFairfax$11K
- Renu Regunathan-ShenkFairfax$6K
- Ranjit CheriyanFairfax$4K
- Ramon MendezWoodbridge$791K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.